羟苯磺酸钙联合阿托伐他汀治疗慢性肾衰竭维持性血液透析患者的随机双盲研究  

A Randomized Double-blind Study on Calcium Dobesilate Combined with Atorvastatin in the Treatment of Patients with Chronic Renal Failure and Maintenance Hemodialysis

作　　者：朱晓青 ZHU Xiaoqing(Xiamen Fifth Hospital,Xiamen 361000,China)

机构地区：[1]厦门市第五医院,福建厦门361000

出　　处：《中外医学研究》2022年第3期30-34,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究羟苯磺酸钙联合阿托伐他汀治疗慢性肾衰竭维持性血液透析患者的临床效果。方法:选取2017年4月-2018年10月厦门市第五医院120例慢性肾衰竭维持性血液透析患者,双盲随机分组,各60例。两组均进行血液透析治疗,于此基础上,对照组予以羟苯磺酸钙治疗,试验组予以羟苯磺酸钙+阿托伐他汀治疗。观察记录两组不良反应情况,并对比两组治疗前后炎症因子水平、营养指标、血脂、肾功能水平。结果:试验组治疗后血清肿瘤坏死因子(TNF)-α、白介素-6(IL-6)及超敏C反应蛋白(hs-CRP)水平均较对照组低(P<0.05);相较于对照组,试验组治疗后血清前白蛋白(PA)、白蛋白(Alb)及血红蛋白(Hb)水平均高(P<0.05);试验组治疗后甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)水平均较对照组低,高密度脂蛋白胆固醇(HDL-C)水平较对照组高(P<0.05);相较于对照组,试验组治疗后血清肌酐(Scr)、尿素氮(BUN)水平均低(P<0.05);试验组不良反应发生率为21.67%(13/60),与对照组的15.00%(9/60)相比,差异无统计学意义(P>0.05)。结论:对慢性肾衰竭维持血液透析患者予以羟苯磺酸钙治疗基础上,加用阿托伐他汀,可有效纠正机体微炎性反应状态,显著改善血脂、肾功能及营养状况,且安全性较高,在临床治疗中具有重要意义。Objective:To investigate the clinical efficacy of Calcium Dobesilate combined with Atorvastatin in the treatment of patients with chronic renal failure and maintenance hemodialysis.Method:From April 2017 to October 2018,120 patients with chronic renal failure and maintenance hemodialysis in Xiamen Fifth Hospital were divided into two groups according the randomized double-blind method,each with 60 cases.The two groups were treated with hemodialysis.On this basis,the control group was treated with Calcium Dobesilate,and the experimental group was treated with Calcium Dobesilate+Atorvastatin.The adverse reactions of two groups were observed.The inflammatory factors levels,nutrition index,blood lipids,and renal function of two groups before and after treatment were compared.Result:The levels of serum TNF-α,IL-6 and hs-CRP in the experimental group were lower than those of the control group after treatment (P<0.05).Compared with the control group,the serum levels of PA,Alb and Hb were higher in the experimental group after treatment (P<0.05).The levels of TG,LDL-C and TC in the experimental group were lower than those in the control group,and the level of HDL-C was higher than that in the control group after treatment (P<0.05).Compared with the control group,the serum levels of Scr and BUN were lower after treatment in the experimental group (P<0.05).There was no significant difference in the incidence of adverse reactions between the experimental group 21.67% (13/60) and control group 15.00% (9/60) (P>0.05).Conclusion:On the basis of patients treated with Calcium Dobesilate,chronic renal failure and maintenance hemodialysis patients treated with Atorvastatin can effectively correct the state of micro inflammatory reaction of the body,significantly improve the blood lipid,renal function and nutritional status.Besides,it has high safety,and it is of great significance in clinical treatment.

关 键 词：慢性肾衰竭 维持性血液透析 羟苯磺酸钙 阿托伐他汀 

分 类 号：R692.5[医药卫生—泌尿科学]